[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100505720":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":32,"locations":38,"responsibleParty":105,"collaborators":108,"id":112,"slug":113,"hasResults":114,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":120,"sex":121,"minAge":122,"maxAge":10,"enrollmentInfo":123,"targetDuration":10,"studyType":126,"phases":10,"briefSummary":127,"conditions":128,"keywords":130,"overallStatus":41,"whyStopped":10,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":146},{"fullName":5,"class":6},"University of Pennsylvania","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Ocular GCA",null,"GCA with clinical diagnosis of ischemic optic neuropathy or other ocular condition",[13],"Diagnostic Test: Magnetic Resonance Imaging (MRI)",{"label":15,"type":10,"description":16,"interventionNames":17},"Non-Ocular GCA","GCA without ocular manifestations",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Non-GCA","Initially suspected to have GCA but final clinical diagnosis not GCA",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"DIAGNOSTIC_TEST","Magnetic Resonance Imaging (MRI)","Combined orbital and cranial vessel wall MRI",[19,15,9],[29],{"name":30,"affiliation":5,"role":31},"Rennie Rhee, MD","PRINCIPAL_INVESTIGATOR",[33],{"name":34,"role":35,"phone":36,"phoneExt":10,"email":37},"Brenda Hernandez-Romero, B.S","CONTACT","917-548-2067","Brenda_Hernandez-Romero@pennmedicine.upenn.edu",[39,58,71,89],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Mayo Building and Gonda Building","RECRUITING","Rochester","Minnesota","55905","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-92.4699,44.02163,{"lat":51,"lon":50},[54],{"name":55,"role":35,"phone":56,"phoneExt":10,"email":57},"Jennifer Sletten","507-284-3695","sletten.jennifer@mayo.edu",{"facility":59,"status":41,"city":60,"state":61,"zip":62,"country":45,"countryCode":46,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"3400 Civic Center Blvd","Philadelphia","Pennsylvania","19104",{"type":48,"coordinates":64},[65,66],-75.16362,39.95238,{"lat":66,"lon":65},[69,70],{"name":34,"role":35,"phone":36,"phoneExt":10,"email":37},{"name":30,"role":31,"phone":10,"phoneExt":10,"email":10},{"facility":72,"status":73,"city":74,"state":75,"zip":76,"country":77,"countryCode":78,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"St. Joseph's Healthcare Hamilton","NOT_YET_RECRUITING","Hamilton","Ontario","L8G 5E4","Canada","CA",{"type":48,"coordinates":80},[81,82],-79.84963,43.25011,{"lat":82,"lon":81},[85],{"name":86,"role":35,"phone":87,"phoneExt":10,"email":88},"Sandra Messier","905-573-4823","smessier@stjosham.on.ca",{"facility":90,"status":73,"city":91,"state":91,"zip":92,"country":93,"countryCode":94,"cosmosGeoPoint":95,"geoPoint":99,"contacts":100},"University Hospital Wuerzburg","Würzburg","97080","Germany","DE",{"type":48,"coordinates":96},[97,98],9.95121,49.79391,{"lat":98,"lon":97},[101],{"name":102,"role":35,"phone":103,"phoneExt":10,"email":104},"Carmen Müglich","49 931 201 40112","Mueglich_C@ukw.de",{"type":31,"investigatorFullName":106,"investigatorTitle":107,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Rennie Rhee, M.D., MSCE","Assistant Professor of Medicine",[109],{"name":110,"class":111},"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","NIH","100505720","vascular-mri-evaluation-in-giant-cell-arteritis-vega-100505720",false,"NCT05865054","Vascular MRI Evaluation in Giant Cell Arteritis (VEGA)","A Longitudinal Study of Orbital and Cranial Vessel Wall MRI in Giant Cell Arteritis by the Vascular MRI Evaluation in Giant Cell Arteritis (VEGA) Collaborative","VEGA","Inclusion Criteria:\n\n* Age 50 years or older\n* First presentation of suspected GCA\n* New or worsening cranial manifestations within 4 weeks of enrollment concerning for active GCA\n* Elevated CRP greater than 1.0 mg\u002Fdl\n* Plan to undergo temporal artery biopsy or ultrasound for diagnosis\n\nExclusion Criteria:\n\n* Contra-indication to receiving MRI including:\n\nImplanted medical devices, pacemaker, and metallic foreign fragments inside body\u002Forbits Known gadolinium allergy Women who are pregnant or nursing\n\n* Absence of cranial symptoms related to GCA (e.g., only large vessel GCA)",true,"ALL","50 Years",{"count":124,"type":125},400,"ESTIMATED","OBSERVATIONAL","The research study is being conducted to determine the utility of magnetic resonance imaging (MRI) in identifying inflammation of arteries supplying blood to the head, brain, and eyes. The target population includes patient with suspected giant cell arteritis (GCA; temporal arteritis).",[129],"Giant Cell Arteritis",[131,132,133,134,135,136],"Temporal Arteritis","Horton's Giant Cell Arteritis","Horton's Disease","Horton Giant Cell Arteritis","Horton Disease","Cranial Arteritis","2025-09-15",{"date":139,"type":140},"2025-09-19","ACTUAL",{"date":142,"type":140},"2020-07-29",{"date":144,"type":125},"2033-07",{"name":5,"class":6},4]